PMID- 37272552
OWN - NLM
STAT- MEDLINE
DCOM- 20230606
LR  - 20230606
IS  - 1607-8454 (Electronic)
IS  - 1024-5332 (Linking)
VI  - 28
IP  - 1
DP  - 2023 Dec
TI  - Bridging to transplant and post-transplant maintenance therapy with FLT3 
      inhibitors in patients with relapsed or refractory FLT3 mutated acute myeloid 
      leukemia.
PG  - 2220518
LID - 10.1080/16078454.2023.2220518 [doi]
AB  - OBJECTIVES AND METHODS: This single-center retrospective study was performed to 
      evaluate the safety and efficacy of FMS-like tyrosine kinase 3 (FLT3) inhibitors 
      before and after allogeneic hematopoietic cell transplantation (HCT) in 
      relapsed/refractory patients with FLT3-mutation positive acute myeloid leukemia 
      (AML). RESULTS: Ten patients who met the eligibility criteria were included. 
      Eight of them achieved hematological remission at HCT, within a median span of 79 
      days (range: 43-197). In post-HCT, patients started maintenance therapy (MT; 
      median time-to-start 79 days, range: 43-197), and the median duration of MT was 
      390 days (range: 67-815). Grade 3 hematological adverse events (AEs) were found 
      in two patients, and non-hematological AEs were found in five patients. Nine 
      patients underwent either dose reduction, discontinuation of therapy, or a switch 
      to another FLT3 inhibitor due to AEs. Disease relapse occurred in one patient 
      during MT. At the time of the last follow-up, seven patients are alive and 
      disease-free, while three have died due to infection or transplant complications. 
      CONCLUSION: In relapsed/refractory FLT3 mutation-positive AML, the use of FLT3 
      inhibitors can lead to high response rates and provide a safe bridge from HCT to 
      MT. If sufficient attention is paid to safety, this therapy is expected to 
      prevent disease relapse even with reduced dosages.
FAU - Hirose, Natsuki
AU  - Hirose N
AD  - Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
FAU - Tachibana, Takayoshi
AU  - Tachibana T
AD  - Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
FAU - Izumi, Akihiko
AU  - Izumi A
AD  - Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
FAU - Sato, Shuku
AU  - Sato S
AD  - Division of Hematology, Shonan Kamakura General Hospital, Kamakura, Japan.
FAU - Tadera, Noriyuki
AU  - Tadera N
AD  - Department of Hematology, Kitasato University School of Medicine, Sagamihara, 
      Japan.
FAU - Tamai, Yotaro
AU  - Tamai Y
AD  - Division of Hematology, Shonan Kamakura General Hospital, Kamakura, Japan.
FAU - Kanamori, Heiwa
AU  - Kanamori H
AD  - Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
FAU - Tanaka, Masatsugu
AU  - Tanaka M
AD  - Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
FAU - Nakajima, Hideaki
AU  - Nakajima H
AD  - Department of Hematology and Clinical Immunology, Yokohama City University School 
      of Medicine, Yokohama, Japan.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Hematology
JT  - Hematology (Amsterdam, Netherlands)
JID - 9708388
RN  - EC 2.7.10.1 (fms-Like Tyrosine Kinase 3)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (FLT3 protein, human)
SB  - IM
MH  - Humans
MH  - fms-Like Tyrosine Kinase 3/genetics
MH  - Phenylurea Compounds/therapeutic use
MH  - Retrospective Studies
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Recurrence
MH  - Mutation
MH  - *Leukemia, Myeloid, Acute/therapy/drug therapy
MH  - Protein Kinase Inhibitors/adverse effects
OTO - NOTNLM
OT  - Acute myeloblastic leukemia
OT  - FLT3 inhibitors
OT  - bridging
OT  - maintenance therapy
OT  - transplantation
EDAT- 2023/06/05 13:05
MHDA- 2023/06/06 06:42
CRDT- 2023/06/05 07:23
PHST- 2023/06/06 06:42 [medline]
PHST- 2023/06/05 13:05 [pubmed]
PHST- 2023/06/05 07:23 [entrez]
AID - 10.1080/16078454.2023.2220518 [doi]
PST - ppublish
SO  - Hematology. 2023 Dec;28(1):2220518. doi: 10.1080/16078454.2023.2220518.